Lyka’s patent pending Drug Pregabalin Gel 8% w/w receives approval from CDSCO
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Aims to achieve CDMO sales of US$ 400 million by 2028
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Revolutionary technology will further boost OneSource’s scientific services offerings
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Subscribe To Our Newsletter & Stay Updated